Peg-IFNa-2a/RBV antiviral efficacy in cirrhotic hepatitis C patients after splenectomy or partial splenic embolization.
10.3760/cma.j.issn.1007-3418.2012.02.009
- Author:
Yu-Mei XIE
1
;
Bing LI
;
Li MA
;
Lei PAN
;
Xin WEI
;
Xue-Juan PENG
;
Chun-Qiu HAO
;
Ying ZHANG
;
Xue-Fan BAI
;
Wen-Zhen KANG
;
Zhan-Sheng JIA
Author Information
1. Center of Diagnosis and Treatment for Infectious Diseases of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
- Publication Type:Clinical Trial
- MeSH:
Adult;
Aged;
Antiviral Agents;
therapeutic use;
Combined Modality Therapy;
Female;
Hepatitis C;
complications;
therapy;
Humans;
Interferon-alpha;
therapeutic use;
Liver Cirrhosis;
etiology;
therapy;
Male;
Middle Aged;
Polyethylene Glycols;
therapeutic use;
Postoperative Period;
Recombinant Proteins;
therapeutic use;
Ribavirin;
therapeutic use;
Splenectomy;
Treatment Outcome
- From:
Chinese Journal of Hepatology
2012;20(2):112-115
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the antiviral efficacy of combination therapy with pegylated-interferon alpha (peg-IFNa)-2a and ribavirin (RBV) in hepatitis C patients with liver cirrhosis after splenectomy or partial splenic embolization. Forty-nine hepatitis C patients with liver cirrhosis who were unable to use antiviral therapy because of hypersplenism were recruited for study and treated with splenectomy or partial splenic embolization. Three months later, a regimen of antiviral combination therapy was initiated with peg-IFNa-2a (once-weekly subcutaneous injection: 135 μg or 180 μg) and RBV (daily oral: 800 to 1200 mg), and was maintained for 48 weeks. The patients were followed up at treatment weeks 1, 2, 4, 6, 8, and 12. Thereafter, follow-up was conducted every four weeks. The patients were observed until 24 weeks after treatment discontinuation. Follow-up testing included liver function, blood chemistry, renal function, and HCV RNA level. Any adverse reactions were recorded. Liver cirrhosis patients complicated by hypersplenism can be treated effectively with peg-IFNa-2a/RBV combination antiviral therapy after splenectomy or partial splenic embolization. The antiviral-induced sustained viral response rates was 65.00% in cirrhotic/hypersplenic hepatitis C patients receiving splenectomy and 58.62% in those receiving partial splenic embolization. Hypersplenism patients with hepatitis C-related cirrhosis achieved a good antiviral therapeutic effect with peg-IFNa-2a/RBV combination therapy following splenectomy or partial splenic embolization. This sequence of treatment may help to decrease incidences of chronic hepatitis C-induced liver failure and liver cancer in these patients.
